Cargando…
Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence
Specific inhibition of the cytokine, tumor necrosis factor-α (TNF), has revolutionized the treatment of patients with several autoimmune diseases, and genetically engineered anti-TNF antibody constructs now constitute a heavy medicinal expenditure in many countries. Unfortunately, up to 30% of patie...
Autor principal: | Bendtzen, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389569/ https://www.ncbi.nlm.nih.gov/pubmed/25904915 http://dx.doi.org/10.3389/fimmu.2015.00152 |
Ejemplares similares
-
Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection
por: Bendtzen, Klaus
Publicado: (2015) -
A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort
por: Duhazé, Julianne, et al.
Publicado: (2020) -
Textbook of immunopharmacology /
Publicado: (1984) -
Immunopharmacology of allergic diseases /
Publicado: (1996) -
Section 4: Immunopharmacology
Publicado: (2017)